Publicacións en colaboración con investigadores/as de Hospital General Universitario de Valencia (15)

2022

  1. RENORT: a project to analyze patterns of care in radiation oncology in Spain

    Clinical and Translational Oncology, Vol. 24, Núm. 7, pp. 1322-1332

2021

  1. Health-related quality of life in men with localized prostate cancer treated with radiotherapy: validation of an abbreviated version of the Expanded Prostate Cancer Index Composite for Clinical Practice in Spain

    Health and Quality of Life Outcomes, Vol. 19, Núm. 1

  2. To the editor, response letter

    Clinical and Translational Oncology

2019

  1. Are there enough radiation oncologists to lead the new Spanish radiotherapy?

    Clinical and Translational Oncology, Vol. 21, Núm. 12, pp. 1663-1672

  2. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database

    Clinical and Translational Oncology, Vol. 21, Núm. 7, pp. 900-909

  3. Survival after biochemical failure in prostate cancer treated with radiotherapy: Spanish Registry of Prostate Cancer (RECAP) database outcomes

    Clinical and Translational Oncology, Vol. 21, Núm. 8, pp. 1044-1051

2018

  1. Adjuvant versus salvage radiotherapy in prostate cancer: multi-institutional retrospective analysis of the Spanish RECAP database

    Clinical and Translational Oncology, Vol. 20, Núm. 2, pp. 193-200

2017

  1. Demand for radiotherapy in Spain

    Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 204-210

2016

  1. Corrigendum to "Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance". [Rep. Pract. Oncol. Radiother. 20 (2015) 259-272]

    Reports of Practical Oncology and Radiotherapy

  2. GRAY-B: An open label multicenter phase-2 GEM study on ipilimumab and radiation in patients with melanoma and brain metastases

    Annals of Oncology, Vol. 27, pp. vi383

  3. The number of risk factors is the strongest predictor of prostate cancer mortality: multi-institutional outcomes of an extreme-risk prostate cancer cohort

    Clinical and Translational Oncology, Vol. 18, Núm. 10, pp. 1026-1033

2015

  1. Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies

    Clinical and Translational Oncology, Vol. 17, Núm. 3, pp. 223-229

  2. Nomogramme für die Prognose eines biochemischen Rezidivs beim Prostatakarzinom nach Strahlentherapie und Androgendeprivationstherapie

    Strahlentherapie und Onkologie, Vol. 191, Núm. 10, pp. 792-800

  3. Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance

    Reports of Practical Oncology and Radiotherapy, Vol. 20, Núm. 4, pp. 259-272

2014

  1. Infrastructures, treatment modalities, and workload of radiation oncology departments in Spain with special attention to prostate cancer

    Clinical and Translational Oncology, Vol. 16, Núm. 5, pp. 447-454